specialist

[키워드] 1:1 24 hour 24 hours achievement addition Administered African age allocation anticipated antiretroviral drugs antiviral activity approval Atazanavir atazanavir/ritonavir Blinding Care clinical Clinical improvement Clinical management Comorbidities confirmation Control control group COVID-19 COVID-19 diagnosis COVID-19 infection criteria defined determined by diagnosed Diagnosis discharge dissemination drug Drug administration drugs Efficacy and safety element eliminated enrolment exclusion criteria food Food and Drug Administration Gender group hospital hypersensitivity include inclusion criteria Infectious diseases information initiation of treatment Interaction intervention group Isolation lactating mechanical ventilation medication moderate moderate to severe multicentre Nasopharyngeal swab negativity Nigeria nitazoxanide number objective Ogun once daily Open-label open-label trial Ordinal Scale outcome measure Pan Pan African Clinical Trials Registry participant Patient PCR PCR test Phase 2 physician polymerase chain polymerase chain reaction positive pregnant Proportion of participant protocol quantified randomisation randomised randomised controlled trial receive receiving recruited REDCap Registered registry reported Ritonavir RT-PCR Saliva Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 polymerase chain reaction SARS-CoV-2 viral load secondary care sequence severe COVID-19 specialist Standard Standard of care state Stratification Study protocol supplementary material symptomatic Teaching Temporal the WHO time Treatment Trial Trial registration university Viral Viral load website working
[DOI] 10.1186/s13063-020-04987-8 PMC 바로가기 [Article Type] Comparative Study